腹腔热化疗治疗卵巢癌合并腹水临床疗效观察  

Clinical study of intraperitoneal thermochemotherapy in the treatment of patients with ovarian cancer and ascites

作　　者：罗展雄[1] 倪秉强[1] 郑青平[1] 陈日新[1] 张志红[1] 徐艺安[1] 李旌[1] 朱州[1] 李家伟[1] 

机构地区：[1]广西医科大学第五附属医院柳州市人民医院肿瘤科,广西柳州545000

出　　处：《中国肿瘤临床与康复》2009年第5期428-430,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨腹腔热化疗治疗卵巢癌合并腹水的疗效及毒副反应。方法将入选病例随机分为两组,治疗组采用腹腔热疗联合腹腔灌注化疗;对照组则仅行腹腔灌注化疗,剂量与治疗组相同,未进行腹腔热疗。结果治疗组卵巢肿瘤治疗总有效率60.5%(23/38),对照组为28.6%(10/35),两组比较差异有显著性(P<0.05);治疗组腹水治疗总有效率84.2%(32/38),对照组为57.1%(20/35),两组比较差异有显著性(P<0.05)。而两组患者治疗前后T淋巴细胞亚群结果比较,差异有显著性(P<0.05)。毒副反应主要为胃肠道反应、骨髓抑制及腹痛,两组毒副反应比较,差异无显著性(P>0.05)。结论热疗联合化疗药物腹腔灌注治疗卵巢癌合并腹水具有协同效应,增强抗癌效果、提高免疫力并抑制肿瘤细胞活性,治疗毒副反应可耐受。Objective To investigate the efficacy and toxic reaction of intraperitoneal thermochemotherapy in the treatment of varian cancer with ascites.Methods Cases selected were randomly divided into therapy group（38 cases）and control group（35 cases）.The therapy group received simultaneous intraperitoneal thermotherapy and intraperitoneal chemotherapy,the control group received only intraperitoneal chemotherapy.Results The overall response rates in the treatment for tumor of the ovary and for ascites were respectively 60. 5% （23/38）, 84. 2% （ 32/38 ） in therapy group and 28.6% （ 10/35 ）, 57. 1% （ 20/35 ） in control group and there was significant difference（ P 〈0. 05）. Comparison of T cell subset in the 2 groups after treatment showed significant difference （ P 〈 0. 05 ）. There was no significant difference in the toxic re- action（ P 〉 0.05 ）. Conclusion Intraperitoneal thermochemotherapy in the treatment of ovarian cancer with ascites has synergistic effect, increases anticaneer effect, raises immunity and inhibits tumour cell activity. Its toxic reaction can be tolerated.

关 键 词：腹腔热化疗 T淋巴细胞亚群 卵巢肿瘤 腹水 

分 类 号：R737.31[医药卫生—肿瘤] R730.58[医药卫生—临床医学]